Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

The FDA approved vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy. Approval was backed by the HELIOS-B trial results of vutrisiran as an add-on to tafamidis or alone vs.

Use code FY25SAVE at checkout. What Is the Current Value of the Vutrisiran Market and Its Expected Growth? The vutrisiran market size has grown rapidly in recent years. It will grow from $0.60 ...

“Data showing beneficial effects on cardiac systolic and diastolic function are novel and indicate the direct impact of vutrisiran in cardiac structure and function of patients living with ATTR-C ...

Vutrisiran (Amvuttra), a small-interfering RNA (siRNA) therapy, is now the third drug approved by the US Food and Drug Administration for the treatment of adults with transthyretin amyloid ...

The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals Inc. and is used to treat transthyretin amyloid cardiomyopathy. Advertisement ATTR-CM is a disease in which harmful ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for vutrisiran for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Treatment with vutrisiran led to a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events. The Food and Drug Administration (FDA ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...